Royalty Accounts Payable from 2010 to 2024

RPRX Stock  USD 26.43  0.03  0.11%   
Royalty Pharma Accounts Payable yearly trend continues to be fairly stable with very little volatility. Accounts Payable is likely to outpace its year average in 2024. Accounts Payable is the amount Royalty Pharma Plc owes to suppliers or vendors for products or services received but not yet paid for. It represents Royalty Pharma's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2000-03-31
Previous Quarter
23.4 M
Current Value
22.1 M
Quarterly Volatility
6.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 196.5 M, Total Revenue of 2.5 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 5.07, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Royalty Pharma Plc over the last few years. An accounting item on the balance sheet that represents Royalty Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Royalty Pharma Plc are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Royalty Pharma's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Royalty Accounts Payable Regression Statistics

Arithmetic Mean6,096,750
Geometric Mean4,477,218
Coefficient Of Variation80.89
Mean Deviation4,061,667
Median4,477,000
Standard Deviation4,931,923
Sample Variance24.3T
Range14.8M
R-Value0.84
Mean Square Error7.9T
R-Squared0.70
Significance0.0001
Slope921,821
Total Sum of Squares340.5T

Royalty Accounts Payable History

202415.9 M
202315.2 M
20227.9 M
20215.6 M
202010.8 M
201911.2 M

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable15.2 M15.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.